SAN DIEGO, California, July 14 --
With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient),
Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to
assess response to Plavix(R), but also its newly approved competitor, Effient.
In obtaining a result from the VerifyNow System, physicians are provided
objective information to determine the response of an individual patient to
their antiplatelet therapy, regardless of the P2Y12 inhibitor that is
prescribed.